Literature DB >> 6604791

Specific involvement of peripheral T lymphocytes against acetylcholine receptors in myasthenia gravis.

B M Conti-Tronconi, A Scotti, A Sghirlanzoni, F Clementi.   

Abstract

A specific sensitisation of blood T lymphocytes against the nicotinic acetylcholine receptor has been demonstrated in myasthenic patients. After thymectomy the T lymphocytes response was quickly decreased and in most patients it reached normal values. The T response remained at low or normal levels for at least two years. In patients who had undergone thymectomy three or more years before, a T lymphocyte response against acetylcholine receptors was frequently detected.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604791      PMCID: PMC1027566          DOI: 10.1136/jnnp.46.9.832

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

1.  Functional activities of rosette separated human peripheral blood leukocytes.

Authors:  J H Dean; J S Silva; J L McCOY; C M Leonard; G B Cannon; R B Herberman
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

2.  Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis.

Authors:  O Abramsky; A Aharonov; C Webb; S Fuchs
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

Review 3.  Myasthenia gravis (first of two parts).

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1978-01-19       Impact factor: 91.245

4.  The thymus in myasthenia gravis. Evidence for altered cell populations.

Authors:  N I Abdou; R P Lisak; B Zweiman; I Abrahamsohn; A S Penn
Journal:  N Engl J Med       Date:  1974-12-12       Impact factor: 91.245

5.  The pathology of the thymus gland in myasthenia gravis.

Authors:  B Castleman
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

6.  Histocompatibility matching. VI. Miniaturization of the mixed leukocyte culture test: a preliminary report.

Authors:  R J Hartzman; M Segall; M L Bach; F H Bach
Journal:  Transplantation       Date:  1971-03       Impact factor: 4.939

7.  Experimental autoimmune myasthenia gravis: cellular and humoral immune responses.

Authors:  V A Lennon; J M Lindstrom; M E Seybold
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

8.  Critical reappraisal of the use of edrophonium (tensilon) chloride tests in myasthenia gravis and significance of clinical classification.

Authors:  K E Osserman; G Genkins
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

9.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

10.  Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor.

Authors:  O Abramsky; A Aharonov; D Teitelbaum; S Fuchs
Journal:  Arch Neurol       Date:  1975-10
View more
  4 in total

1.  Antibodies to acetylcholine receptors in myasthenia gravis. In vitro synthesis by peripheral blood lymphocytes before and after thymectomy.

Authors:  J B Kuks; P C Limburg; H J Oosterhuis; T H The
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Acetylcholine receptor-specific suppressive T-cell factor from a retrovirally transformed T-cell line.

Authors:  F Sinigaglia; C Gotti; R Castagnoli; F Clementi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

4.  Thymectomy in myasthenia with pure ocular symptoms.

Authors:  F Schumm; H Wiethölter; A Fateh-Moghadam; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-04       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.